Skip to Content
Merck
CN

Key Documents

View All Documentation

485A-1

ATRX Rabbit Polyclonal Antibody

Synonym(s):

ATP-dependent helicase ATRX, X-linked helicase II, X-linked nuclear protein (XNP)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41116161
Conjugate:
unconjugated
Species reactivity:
human
Application:
ICC
Citations:
6
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

rabbit blood

Quality Level

100, 500

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL (concentrate (485A-14)), vial of 0.1 mL (concentrate (485A-14-RUO) Research Use Only), vial of 0.5 mL (concentrate (485A-15)), vial of 1.0 mL (concentrate (485A-16)), vial of 1.0 mL (concentrate (485A-16-RUO) Research Use Only), vial of 1.0 mL (concentrate (485A-17-RUO) Research Use Only), vial of 1.0 mL (pre-dilute ready-to-use (485A-17)), vial of 7.0 mL (concentrate (485A-18-RUO) Research Use Only), vial of 7.0 mL (pre-dilute ready-to-use (485A-18))

manufacturer/tradename

Cell Marque®

technique(s)

immunocytochemistry: suitable (formalin-fixed, paraffin-embedded sections 1:50-1:50 (concentrated))

isotype

IgG

control

astrocytoma, brain, glioblastoma, oligodendroglioma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

General description

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Analysis Note

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Try our Product Selector Tool to narrow your options

Storage Class

12 - Non Combustible Liquids

wgk

WGK 2

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000528633
0000528631
0000526572
0000528631
0000528633

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniel J Brat et al.
The New England journal of medicine, 372(26), 2481-2498 (2015-06-11)
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly
Akane Yamamichi et al.
Brain tumor pathology, 35(2), 106-113 (2018-03-20)
The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined.
Matthew D Wood et al.
Diagnostic pathology, 14(1), 29-29 (2019-04-11)
Insights into the molecular underpinnings of primary central nervous system tumors have radically changed the approach to tumor diagnosis and classification. Diagnostic emphasis has shifted from the morphology of a tumor under the microscope to an integrated approach based on
View All Related Papers